FermaVir: preclinical data show FV-100 inhibits varicella zoster virus more quickly than acyclovir

By Lisa Kerner

Charlotte, N.C., Aug. 30 - FermaVir Pharmaceuticals, Inc. said preclinical studies show that its FV-100 compound for shingles inhibited the varicella zoster virus that causes shingles 20 hours sooner than acyclovir, a currently approved therapy for shingles.

FermaVir used the EC50, a measure of the amount of a compound which inhibits 50% of the virus in vitro.

"Not only does this data confirm our previous oral bioavailability data in other models but it also suggests that the properties of our compound will enhance it getting to the site of the viral infection and inhibiting the infection much faster than one of the approved drugs," chief executive officer Geoffrey Henson said in a company news release.

FermaVir is an emerging biotechnology company located in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.